Navigation Links
AlphaRx Provides Corporate and Development Update

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to provide shareholders with an update on recent corporate developments.

TSX Venture Exchange Application


AlphaRx is seeking a listing with the TSX Venture Exchange. Research Capital Corporation is sponsoring the application. AlphaRx is in the process of raising up to $1,800,000 U.S. via a private placement in conjunction with the listing application. AlphaRx has been in correspondence with the TSX Venture Exchange and has responded to all comments raised to-date.

Corporate Website


AlphaRx is working on a new and improved corporate website which will reflect all current business focus. This new website will be launched some time in June.

Product Development


AlphaRx's current focus is on the development of "nanobiotics" for the treatment of severe pneumonias. AlphaRx's high-priority development programs include Vansolin(TM) and Zysolin(TM).

Vansolin(TM), a specially-formulated Vancomycin nano-particulate formulation, is intended for the treatment of severe pneumonias caused by MRSA (Methicillin Resistant Staphylococcus Aureus) pathogens. Vansolin(TM) is undergoing pivotal animal studies. The Company will make a go/no go decision based on the outcome on these studies which will be available by mid-July.

Zysolin(TM), a specially-formulated Tobramycin nano-particulate formulation, intended for the treatment of severe pneumonias caused by gram negative pathogens such as Psedomonas Aeruginosa. The Company is developing Zysolin(TM) as a primary therapy for Cystic Fibrosis and an adjunctive therapy for ventilated patients with hospital-acquired, Gram-negative pneumonias. Zysolin(TM) is undergoing pivotal animal studies.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Copyright @ 2008. AlphaRx Inc.

SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRxs Indaflex(TM) Continues its Clinical Development
2. AlphaRx CEO Accumulates More Company Shares
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx Announces Debt Conversion
5. AlphaRx To Present at 47th Annual ICAAC
6. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
7. Cipher provides regulatory update for CIP-TRAMADOL ER
8. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
9. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
10. Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain
11. Dubai Provides Aid for Cyclone Nargis Victims In Myanmar
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
Breaking Medicine Technology: